Moderna's 109% Stock Surge: What It Means for Global Health and mRNA Vaccines
Moderna’s financial rebound could accelerate the deployment of mRNA technology for RSV, flu, and future pandemics, enhancing public health resilience.
Cross-Sector entity
COVID-19 Vaccine
ProductCOVID-19 Vaccine is most often covered alongside Cytomegalovirus (CMV) candidate, which appears in 3 of these 4 stories. That works out to roughly 0.2 stories per week across a 119-day span. The busiest single day carried 3. fda-approval accounts for 1 of the 4 tracked stories, while 3 other categories carry the remainder.
4 verified stories tracked
Last mentioned: Jul 21, 2026
Entity pulse
Recent coverage · COVID-19 Vaccine
↑
4 stories
avg impact
100% positive
0% negative
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
What the coverage shows about COVID-19 Vaccine
COVID-19 Vaccine is most often covered alongside Cytomegalovirus (CMV) candidate, which appears in 3 of these 4 stories. That works out to roughly 0.2 stories per week across a 119-day span. The busiest single day carried 3. fda-approval accounts for 1 of the 4 tracked stories, while 3 other categories carry the remainder. Each carries 5 original sources on average. We currently track 4 Cross-Sector stories that mention COVID-19 Vaccine, published between March 25, 2026 and July 21, 2026.
- Stories tracked
- 4
- Per week
- 0.2
- Sources per story
- 5
Computed from the 4 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering COVID-19 Vaccine. Shared-story counts are live from our verified record — not editorial picks.
Timeline
-
Cramer Endorsement & 109% YTD Gain
Motley Fool highlights 109% year-to-date surge and Jim Cramer's comment that Moderna is 'finally investable again'.
-
Quarterly Update
Moderna reports a 26% reduction in operating expenses, reiterates up to 10% revenue growth target for 2026.
-
Post-Pandemic Decline
Demand for COVID vaccines wanes, RSV sales miss expectations, and CMV candidate fails; stock loses over 80% from peak.
-
COVID Vaccine Success
Moderna's COVID-19 vaccine drives record revenue; stock surges over 2,000% from early 2020 through August 2021.
Stories mentioning COVID-19 Vaccine 4
Moderna Up 109% YTD: Cramer Calls It Investable—Is It a Buy on the Dip?
Jim Cramer’s bullish pivot comes as Moderna stock pulls back from its 109% YTD gain, raising the question: does the dip offer a compelling entry for investors?
After 109% Rally, Moderna’s Pipeline Progress and 10% Revenue Goal
Moderna’s cost cuts and pipeline milestones, from RSV commercialization to latent virus programs, are restoring biotech investor confidence despite past setbacks.
Source: Adria Cimino (us) · fool.com
Large Study Confirms Maternal COVID-19 Vaccination Protects Infants Post-Birth
A comprehensive multi-site study has confirmed that COVID-19 vaccination during pregnancy significantly reduces the risk of hospitalization for infants in their first six months of life. The findings provide robust evidence for the benefits of transplacental antibody transfer in protecting neonates who are not yet eligible for vaccination.
Source: publicradiotulsa.org · wcsufm.org